For the xenograft with low expression of CD138, only the combination of indatuximab ravtansine and docetaxel was significantly superior to control (Fig. 5b), and this regimen had high and very high anti-tumor activity with minimum T/C values of 16.3% and 8.3%, respectively. This evidence concerns the gene SDC1 and neoplasm.